BioTek wins Extraordinary New Product Line award for Cytation 3 Cell Imaging Multi-Mode Reader

NewsGuard 100/100 Score

BioTek Instruments, Inc., received Thermo Fisher Scientific's "Extraordinary New Product Line" award for their Cytation 3 Cell Imaging Multi-Mode Reader. The award was presented at the Fisher Scientific North America Sales Meeting, held February 24-26, 2014 in Denver, Colorado. Cytation 3 was recognized by Fisher Scientific's product management team for its innovative technology and successful sales performance.

"We're proud to have Fisher Scientific as a strong partner, and honored to receive this award," noted Gary Barush, Director of Marketing and Sales at BioTek Instruments. "Together, and with Cytation 3's combination of cellular imaging and multi-mode microplate detection, we can continue to provide unique workflow solutions to any laboratory."

BioTek's patent pending Cytation™ 3 Cell Imaging Multi-Mode Reader combines automated digital fluorescence microscopy and conventional microplate detection in a modular and upgradable platform. This allows for quantitative and phenotypic cellular analyses, and especially for live cell assays where Cytation 3's temperature control and available gas control module support the ideal environment to grow, image, count and further analyze cells in microplates and other sample vessels. Cytation 3 is the recipient of two additional awards since its launch: MipTec New Product Innovation Award and the SelectScience "Scientists' Choice Award for Best Drug Discovery Product" Award. It is also a finalist in the 2014 Edison Awards® competition.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
NK cells' role in cancer therapy resistance unveiled